English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Summary   Background  Duloxetine has been approved in the United States, European Union and some Asian countries for the treatment of diabetic peripheral neuropathic pain ( DPNP ). We assessed the efficacy and safety of duloxetine (60 mg once daily) compared with placebo in Chinese patients suffering from  DPNP .    Methods  This was a phase 3, multicenter, randomised, double‐blind, parallel, placebo‐controlled, 12‐week trial of the treatment of  DPNP  with duloxetine. Subjects were male and female outpatients ≥ 18 years of age with  DPNP , as assessed by the Michigan Neuropathy Screening Instrument, and had a rating of ≥ 4 on the Brief Pain Inventory‐Modified Short Form‐Severity weekly average pain item. The primary efficacy measure was the reduction in pain severity from baseline to 12 weeks, as measured by the weekly mean of 24‐h average pain ratings recorded in the patient's diary. Mean changes from baseline in efficacy measures were analysed by a restricted maximum likelihood‐based, mixed‐effects model repeated measures approach and by analysis of covariance.    Results  Of the 405 patients randomised, 203 patients were assigned to duloxetine 60 mg once daily and 202 patients were assigned to placebo. Duloxetine‐treated patients showed significantly greater pain relief on 24‐h average pain ratings compared with placebo‐treated patients each week of the 12‐week study period [week 12: least squares ( LS ) mean change duloxetine: −2.40, placebo: −1.97;  LS  mean change difference (95% confidence interval) = −0.43 (−0.82, −0.04), p = 0.030]. Compared with placebo, patients treated with duloxetine experienced higher rates of nausea (p = 0.010), somnolence (p &lt; 0.001) and asthenia (p = 0.002).    Conclusions  Duloxetine‐treated patients showed significantly greater pain relief compared with placebo‐treated patients over the 12‐week study period. Duloxetine was shown in Chinese patients to have a safety profile similar to that found in previous duloxetine trials.

Treatment of patients with diabetic peripheral neuropathic pain in China: a double‐blind randomised trial of duloxetine vs. placebo